|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | MicroRNAs as a potential prognostic factor in gastric cancer显示文摘AIM:To compare the microRNA (miR) profiles in the primary tumor of patients with recurrent and non-recurrent gastric cancer.METHODS:The study group included 45 patients who underwent curative gastrectomies from 1995 to 2005 without adjuvant or neoadjuvant therapy and for whom adequate tumor content was available.Total RNA was extracted from formalin-fixed paraffin-embedded tumor samples,preserving the small RNA fraction.Initial profiling using miR microarrays was performed to identify potential biomarkers of recurrence after resection.The expression of the differential miRs was later verified by quantitative real-time polymerase chain reaction (qRT-PCR).Findings were compared between patients who had a recurrence within 36 mo of surgery (bad-prognosis group,n=14,31%) and those who did not (good-prognosis group,n=31,69%).RESULTS:Three miRs,miR-451,miR-199a-3p and miR-195 were found to be differentially expressed in tumors from patients with good prognosis vs patients with bad prognosis (P<0.0002,0.0027 and 0.0046 respectively).High expression of each miR was associated with poorer prognosis for both recurrence and survival.Using miR-451,the positive predictive value for non-recurrence was 100% (13/13).The expression of the differential miRs was verified by qRT-PCR,showing high correlation to the microarray data and similar separation into prognosis groups.CONCLUSION:This study identified three miRs,miR-451,miR-199a-3p and miR-195 to be predictive of recurrence of gastric cancer.Of these,miR-451 had the strongest prognostic impact. | Baruch Brenner Moshe B Hoshen Ofer Purim Miriam Ben David Karin Ashkenazi Gideon Marshak Yulia Kundel Ronen Brenner Sara Morgenstern Marisa Halpern Nitzan Rosenfeld Ayelet Chajut Yaron Niv Michal Kushnir | 2011 | World Journal of Gastroenterology2011，17，35： | 31 |
| 2 | Role of antibiotics for treatment of inflammatory boweldisease显示文摘Inflammatory bowel disease is thought to be caused by an aberrant immune response to gut bacteria in a genetically susceptible host. The gut microbiota plays an important role in the pathogenesis and complications of the two main inflammatory bowel diseases: Crohn's disease(CD) and ulcerative colitis. Alterations in gut microbiota, and specifically reduced intestinal microbial diversity, have been found to be associated with chronic gut inflammation in these disorders. Specific bacterial pathogens, such as virulent Escherichia coli strains, Bacteroides spp, and Mycobacterium avium subspecies paratuberculosis, have been linked to the pathogenesis of inflammatory bowel disease. Antibiotics may influence the course of these diseases by decreasing concentrations of bacteria in the gut lumen and altering the composition of intestinal microbiota. Different antibiotics, including ciprofloxacin, metronidazole, the combination of both, rifaximin, and anti-tuberculous regimens have been evaluated in clinical trials for the treatment of inflammatory bowel disease. For the treatment of active luminal CD, antibiotics may have a modest effect in decreasing disease activity and achieving remission, and are more effective in patients with disease involving the colon. Rifamixin, a non absorbable rifamycin has shown promising results. Treatment of suppurative complications of CD such as abscesses and fistulas, includes drainage and antibiotic therapy, most often ciprofloxacin, metronidazole, or a combination of both. Antibiotics might also play a role in maintenance of remission and prevention of post operative recurrence of CD. Data is more sparse for ulcerative colitis, and mostly consists of small trials evaluating ciprofloxacin, metronidazole and rifaximin. Most trials did not show a benefit for the treatment of active ulcerative colitis with antibiotics, though 2 meta-analyses concluded that antibiotic therapy is associated with a modest improvement in clinical symptoms. Antibiotics show a clinical benefit when used for the treatment of pouchitis. The downsides of antibiotic treatment, especially with recurrent or prolonged courses such as used in inflammatory bowel disease, are significant side effects that often cause intolerance to treatment, Clostridium dificile infection, and increasing antibiotic resistance. More studies are needed to define the exact role of antibiotics in inflammatory bowel diseases. | Orna Nitzan Mazen Elias Avi Peretz Walid Saliba | 2016 | World Journal of Gastroenterology2016，22，3： | 14 |
| 3 | Clostridium difficile and inflammatory bowel disease: Role in pathogenesis and implications in treatment显示文摘Clostridium difficile(C.difficile)is the leading cause of antibiotic associated colitis and nosocomial diarrhea.Patients with inflammatory bowel disease(IBD)are at increased risk of developing C.difficile infection(CDI),have worse outcomes of CDI-including higher rates of colectomy and death,and experience higher rates of recurrence.However,it is still not clear whether C.difficile is a cause of IBD or a consequence of the inflammatory state in the intestinal environment.The burden of CDI has increased dramatically over the past decade,with severe outbreaks described in many countries,which have been attributed to a new and more virulent strain.A parallel rise in the incidence of CDI has been noted in patients with IBD.IBD patients with CDI tend be younger,have less prior antibiotic exposure,and most cases of CDI in these patients represent outpatient acquired infections.The clinical presentation of CDI in these patients can be unique-including diversion colitis,enteritis and pouchitis,and typical findings on colonoscopy are often absent.Due to the high prevalence of CDI in patients hospitalized with an IBD exacerbation,and the prognostic implications of CDI in these patients,it is recommended to test all IBD patients hospitalized with a disease flare for C.difficile.Treatment includes general measures such as supportive care and infection control measures.Antibiotic therapy with either oral metronidazole,vancomycin,or the novel antibiotic-fidaxomicin,should be initiated as soon as possible.Fecal macrobiota transplantation constitutes another optional treatment for severe/recurrent CDI.The aim of this paper is to review recent data on CDI in IBD:role in pathogenesis,diagnostic methods,optional treatments,and outcomes of these patients. | Orna Nitzan Mazen Elias Bibiana Chazan Raul Raz Walid Saliba | 2013 | World Journal of Gastroenterology2013，19，43： | 12 |
| 4 | Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up显示文摘 | Shira Zelber-Sagi Roni Lotan Amir Shlomai Muriel Webb Gil Harrari Assaf Buch Dorit Nitzan Kaluski Zamir Halpern Ran Oren | 2012 | Journal of Hepatology2012，，5： | 4 |
| 5 | Non‐alcoholic fatty liver disease independently predicts prediabetes during a 7‐year prospective follow‐up显示文摘 | Shira Zelber‐Sagi Roni Lotan Oren Shibolet Muriel Webb Assaf Buch Dorit Nitzan‐Kaluski Zamir Halpern Erwin Santo Ran Oren | 2013 | Liver Int2013，，9： | 3 |
| 6 | Systemic lupus erythematosus and innammatory bowel disease 显示文摘 | NITZAN O ELIAS M SALIBA WR | 2006 | Eur J Intern Med2006，17，5： | 1 |
| 7 | Diffusion in polymer electrolytes and the dynamic percolation model显示文摘 | Durr O Dieterich W Nitzan A | 2002 | Solid State Ionics2002，149，： | 1 |
| 8 | A dynamic lattice Monte Carlo model of ion transport in inhomogeneous dielectric environments: Method and implementation 显示文摘 | Graf P Nitzan A Kumikova M G | 2000 | J Phys Chem B2000，10，： | 1 |
| 9 | ALA induced photodynamic effects on Gram positive and negative bacteria显示文摘 | NITZAN Y SALMON-DIVON M SHPOREN E | 2004 | Photochemical & Photobiological Sciences2004，3，5： | 1 |
| 10 | Automatic noninvasive measurement of arterial blood pressure显示文摘 | Nitzan M | 2011 | IEEE Instrumentation & Measurement Magazine2011，14，1： | 1 |
| 11 | Vegetative compatibility groups in Colletotrichum coccodes,the causal agent of black dot on potato显示文摘 | NITZAN N HAZANOVSKY M TAL M | 2002 | Phytopathology2002，92，8： | 1 |
| 12 | New trends in photobiology: bactericidal effect of photoactivated porphyrins-an alternative approach to antimierobial drugs显示文摘 | Malik Z Hanania J Nitzan Y | 1990 | J Photochem Photobilo B Biol1990，，5： | 1 |
| 13 | Effect of external pressure on arteries distal to the cuff during sphygmomanometer显示文摘 | NITZAN M ROSENFELD C WEISS A T | 2005 | IEEE Trans Biomed Eng2005，52，6： | 1 |
| 14 | Surgical management of tem- poromandibular joint ankylosis Type III by retaining the displaced condyle and disc 显示文摘 | Nitzan DW Bar-Ziv J Shteyer A | 1998 | J Oral Maxillofac Surg1998，10，8： | 1 |
| 15 | Pericoronitis : n reappraisal of itsclinical and microbiologic aspects 显示文摘 | Nitzan DW Tal 0 Sela MN | 2003 | J Oral Maxillofac surg2003，43，7： | 1 |
| 16 | Etiology of community - ac- quired pneumonia in hospitalized patients in northern Israel 显示文摘 | Shibli F Chazan B Nitzan O | 2010 | Med Assoc J2010，12，8： | 1 |
| 17 | New trends in photobiology:bactericidal effect of photoactivated porphyrins-an alternative approach to antimicrobial drugs显示文摘 | MALIK Z HANANIA J NITZAN Y | 1990 | J Photochem Photobiol B Biol1990，5，： | 1 |
| 18 | ALA induced photodynamic effects on gram positive and negative bacteria显示文摘 | Nitzan Y Salmon-Divon M Shporen E et o1 | 2004 | Photochemical & Photobiological Sciences2004，3，5： | 1 |
| 19 | Optimal decision rules in uncertain dichotomous choice situation 显示文摘 | Nitzan S Paroush J | 1982 | International Economic Review1982，23，： | 1 |
| 20 | Molecular and structural characterization of the HMP-AB gene encoding a poreforming protein from a clinical isolate of Acinetobacter baumannii 显示文摘 | Gribun A Nitzan Y Pechatnikov I | 2003 | Curr Microbiol2003，47，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员